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The chemokine receptor CXCR4 and its ligand CXCL12 play an important homeostatic
function by mediating the homing of progenitor cells in the bone marrow and
regulating their mobilization into peripheral tissues upon injury or stress. Although the
CXCL12/CXCR4 interaction has long been regarded as a monogamous relation, the
identification of the pro-inflammatory chemokine macrophage migration inhibitory factor
(MIF) as an important second ligand for CXCR4, and of CXCR7 as an alternative receptor
for CXCL12, has undermined this interpretation and has considerably complicated the
understanding of CXCL12/CXCR4 signaling and associated biological functions. This
review aims to provide insight into the current concept of the CXCL12/CXCR4 axis in
myocardial infarction (MI) and its underlying pathologies such as atherosclerosis and
injury-induced vascular restenosis. It will discuss main findings from in vitro studies,
animal experiments and large-scale genome-wide association studies. The importance of
the CXCL12/CXCR4 axis in progenitor cell homing and mobilization will be addressed, as
will be the function of CXCR4 in different cell types involved in atherosclerosis. Finally, a
potential translation of current knowledge on CXCR4 into future therapeutical application
will be discussed.
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INTRODUCTION
Chemokines are small 8-12 kDa cytokines that mediate cell
chemotaxis and arrest by binding to their respective receptors on
the cell surface (Blanchet et al., 2012) (Box 1). The chemokine
receptor CXCR4 and its ligand CXCL12, also known as stromal
cell-derived factor 1 (SDF-1), are attractive therapeutic targets in
the treatment of cancer, as they support migration, proliferation,
and survival of cancer cells (Teicher and Fricker, 2010; Domanska
et al., 2013). Also, CXCR4 is intensively studied in different
autoimmune diseases, including rheumatoid arthritis, systemic
lupus erythematosus, and autoimmune disorders of the central
nerve system asmultiple sclerosis, for its involvement in leukocyte
chemotaxis in specific inflammatory conditions (Debnath et al.,
2013; Domanska et al., 2013). Furthermore, the CXCL12/CXCR4
axis plays a crucial role in the homing of stem and progenitor
cells in the bone marrow and controls their mobilization into
peripheral blood and tissues in homeostatic conditions as well
as after tissue injury or stress. Small molecule CXCR4 inhibitors
are intensively being studied as mobilizers of hematopoietic
stem cells for transplantation therapy of patients with specific
types of cancer (Debnath et al., 2013) (Box 2). Upregulation
of CXCL12 in hypoxic conditions with subsequent mobilization
of CXCR4-positive stem and progenitor cells (Ceradini et al.,
2004) has prompted researchers to explore the role and ther-
apeutic value of progenitor cells and the CXCL12/CXCR4 axis
in diverse models of ischemic injury, including in heart, kidney,
lung, and brain. In addition, CXCL12/CXCR4-mediated mobi-
lization of progenitor cells has also been intensively investigated
in models of vascular injury-induced restenosis as observed after
e.g., organ transplantation, balloon angioplasty, or stent implan-
tation (Schober et al., 2006), as will be discussed in more detail
later. Also, CXCR4 acts as an important coreceptor for human
immunodeficiency virus (HIV) facilitating its entry in host CD4+
T-cells. In fact, the low-molecular weight CXCR4 antagonist
AMD3100, the prototype of a group of so-called bicyclams, was
originally identified in 1994 as a highly potent inhibitor of HIV
replication in human T-cells. Only 3 years later, it was unrav-
eled that blockade of CXCR4 was the underlying mechanism
of the HIV inhibitory function of AMD3100 (De Clercq, 2000;
Debnath et al., 2013). Taken together, it is not surprising that
the CXCL12/CXCR4 axis is one of the most studied chemokine
ligand/receptor axes in a diversity of pathological disorders.
Here we will focus on the role of CXCR4 in coronary artery dis-
ease (CAD) (Box 3). This pathology is caused by atherosclerosis,
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Box 1 | Chemokines.
Chemokines constitute the largest family of cytokines and are defined as small molecules that trigger chemotaxis of cells along a con-
centration gradient. They are generally important in cell signaling (Bachelerie et al., 2014). Although chemokines are a large family, they
all have the same basic structure, known as the chemokine fold, which consists of a short N-terminal region, an extended N-loop region,
followed by three β-strands and one α-helix (Rajagopalan and Rajarathnam, 2006). To date, chemokines have been classified into four major
subdivisions, being C-, CXC-, CC-, and CX3C-chemokines. This classification is based on the number and spacing of conserved N-terminal
cysteine groups, which form disulfide bonds and are hence crucial for the spatial arrangement and stability of the chemokine (Rajagopalan
and Rajarathnam, 2006). In addition to these classical chemokine groups, chemokine-like function (CLF) chemokines have recently been
suggested to form a fifth subclass, which does not have the classical chemokine fold and N-terminal residues, but nevertheless exerts
typical chemokine activities (Tillmann et al., 2013).
The chemokine receptors are classified according to the chemokines they bind and are divided into two groups, being G-protein-
coupled receptors (GPCRs) and atypical chemokine receptors. GPCRs generally signal by activating G-proteins, leading to a plethora of
cellular functions, whereas atypical chemokine receptors appear to shape chemokine gradients and scavenge chemokines in the context of
inflammation independent of G-protein signaling (Bachelerie et al., 2014). Apart from the classical function of cell recruitment, chemokines
also mediate arrest of rolling leukocytes through activation of integrins. Some chemokines, like CXCL12, also have a role in cell homeosta-
sis, which together with chemotaxis and arrest is an important regulatory factor of atherogenesis, as discussed in detail recently (Zernecke
and Weber, 2014).
Box 2 | CXCR4 Antagonists.
AMD3100, also known as Plerixafor or Mozobil (Genzyme Corp), is the first CXCR4 antagonist that has been approved by the FDA as
mobilizer of hematopoietic stem cells in combination with G-CSF in treatment of patients with non-Hodgkin’s lymphoma and multiple
myeloma, and many other small molecule inhibitors of CXCR4 are under investigation or in clinical trial for different pathological settings,
as recently discussed in detail (Debnath et al., 2013). AMD3100 is the prototype of bis-tetraazamacrocycles (bicyclams), a class of highly
potent HIV1 antagonists. Subsequent studies examining the effect of structural modifications of AMD3100 on pharmacokinetic properties
led to the discovery of AMD3465, a monocyclam analog of AMD3100, in which the second cyclam ring of AMD3100 was substituted by a
pyridinylmethylene group. Similarly as AMD3100, AMD3465 interferes with the binding of CXCL12 to CXCR4, thereby preventing CXCL12
to trigger CXCR4 endocytosis and CXCR4-induced intracellular signaling as calcium mobilization and MAPK activation. As an advantage,
AMD3465 shows a 10-fold higher effectiveness in inhibiting CXCR4 activity compared to AMD3100, but has no FDA approval to date and
hence is less used in studies (Hatse et al., 2005).
Box 3 | Cardiovascular Disease.
Cardiovascular disease, including ischemic stroke and heart attack, is a leading cause of death and morbidity worldwide. Its underlying
pathology, atherosclerosis, is defined as a chronic inflammatory disease of arterial walls (Hansson and Hermansson, 2011; Weber and
Noels, 2011). Atherosclerotic lesion formation is initiated by dysfunction of the endothelial layer lining the arterial wall, caused by irritative
stimuli such as dyslipidemia. Upon endothelial activation, monocytes start adhering to and migrating through the endothelium. Monocyte-
derived macrophages in the arterial wall take up cholesterol-rich LDL particles, leading to the formation of so-called foam cells. As the
atherosclerotic lesion progresses, smooth muscle cells (SMCs) migrate from the media to the intima, resident intimal SMCs proliferate
and extracellular matrix molecules such as elastin, collagen and proteoglycans are synthesized. A necrotic core made of extracellular lipids
derived from necrotic and apoptotic foam cells forms in advanced plaques, along with a fibrous cap consisting of collagen and SMCs.
The ultimate complications of atherosclerosis are flow-limiting stenosis and plaque rupture, the latter triggering vessel occlusion through
thrombus formation.
a chronic inflammatory disease of the vessel wall character-
ized by the development of lesions through continuous and
progressive infiltration and accumulation of lipids and leuko-
cytes (Hansson and Hermansson, 2011; Weber and Noels, 2011).
Restriction of the blood flow by extensive lesions or thrombus for-
mation caused by rupture of unstable plaques is a main cause
for myocardial ischemia and infarction. Interventions such as
balloon angioplasty or stent implantation aim to re-open the
occluded artery, but are often associated with a re-narrowing of
the vessel lumen (restenosis) caused by injury-induced vascular
remodeling and neointimal hyperplasia. Bypass grafting remains
the gold standard therapy for severe, diffuse coronary artery occlu-
sion, particularly in the elderly and patients with diabetes. In
this context vein graft failure is a major problem and late vein
graft failure is associated with neointimal hyperplasia and accel-
erated atherosclerosis. Interestingly, recent genome-wide associa-
tion studies (GWAS) revealed CXCL12 as an important candidate
gene associated with CAD and myocardial infarction (MI), but
the underlying mechanisms remain totally unclear (Burton et al.,
2007; Samani et al., 2007; Kathiresan et al., 2009; Farouk et al.,
2010; Schunkert et al., 2011) (Box 4).
To facilitate future research exploring the role of CXCL12 and
CXCR4 in CAD, this review aims to discuss the current concept of
the CXCL12/CXCR4 axis in atherosclerosis, injury-induced vas-
cular restenosis and MI in relation to its role in progenitor cell
mobilization and biological functions in atherosclerosis-relevant
cell types. We will also introduceMIF as an alternative chemokine
ligand for CXCR4, and CXCR7 as an additional receptor for
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CXCL12, to emphasize the complexity of identifying specific
CXCL12- and CXCR4-associated functions through intertwining
of chemokine (receptor) signaling.
CXCR4 AS A CHEMOKINE RECEPTOR FOR CXCL12 AND MIF
CXCR4 AND ITS CHEMOKINE LIGAND CXCL12
The chemokine receptor CXCR4 belongs to the family of seven-
span transmembrane G-protein-coupled chemokine receptors
(GPCRs). It is ubiquitously expressed and evolutionary con-
served, with 89% of similarity between the human and mouse
protein. In 1996 SDF-1, later called CXCL12, was identified as a
ligand for CXCR4 (Bleul et al., 1996a; Oberlin et al., 1996). Similar
as CXCR4, CXCL12 is highly conserved, with human and mouse
showing around 92% amino acid (aa) identity for both ubiqui-
tously expressed isoforms α (89 aa) and β (93 aa) (Shirozu et al.,
1995). Except for these 2 classical isoforms, which are so far func-
tionally indistinguishable and differ only in 4 amino acids at the
C-terminal end, four additional isoforms have been identified in
humans. These γ (119 aa), δ (140 aa), ε (90 aa), and φ (100 aa) iso-
forms show a more restricted expression pattern and have been
much less studied. They result from differential splicing and only
differ at their C-terminal region (Yu et al., 2006) (Figure 1).
Mice deficient forCxcl12 orCxcr4 die perinatally due to defects
in hematopoiesis, vasculo-, cardio-, and neurogenesis (Nagasawa
et al., 1996; Ma et al., 1998; Tachibana et al., 1998; Zou et al.,
1998; Ara et al., 2005). The importance of the CXCL12/CXCR4
axis in embryonic development is associated with an essential
role in homeostatic (progenitor) cell migration. This clarifies
the classification of the CXCL12/CXCR4 axis into the “home-
ostatic/constitutive” chemokine ligand/receptor group, instead
of the “inflammatory/inducible” group of chemokines, which
groups chemokines that are upregulated during inflammation to
drive immune responses (Bachelerie et al., 2014). The CXCR4
receptor and its ligand CXCL12 are mostly studied for their
crucial role in the homing of (hematopoietic) progenitor cells
in the bone marrow and their mobilization into the periphery
in physiological and pathological conditions. Furthermore, the
CXCL12/CXCR4 axis is involved in chemotaxis, cell arrest, angio-
genesis, and cell survival. These functions explain not only the
interest of oncologists in CXCR4, but also underlie the involve-
ment of the CXCL12/CXCR4 axis in CAD, as will be discussed in
more detail later.
Binding of CXCL12 to CXCR4 mediates intracellular signal-
ing through a classical heterotrimeric G-protein, composed of
an Gα, Gβ, and Gγ subunit. Of the 4 general classes of Gα
proteins, named Gαs, Gαi, Gαq, and Gα12, CXCR4 signaling
seems mainly coupled to the Gαi subunit. Receptor stimulation
induces the dissociation of the heterotrimeric G-protein. The Gαi
monomer inhibits adenylyl cyclase activity and triggers MAPK
and PI3K pathway activation, whereas the Gβγ dimer triggers
Box 4 | Genome-wide Association Studies.
Genome-wide association studies (GWAS) have emerged as a very powerful tool in medical research over the last decade. In association
studies, the frequency of alleles or genotype-variants is compared between disease cases and controls. GWAS apply this principle to
the whole genome, i.e., a dense set of single nucleotide polymorphisms (SNPs) across the whole genome is genotyped to find out the
most common variation of SNP patterns in a disease of interest (Hirschhorn and Daly, 2005). This method is a comprehensive, unbiased
approach to identify genes which are regulated in a disease of interest.
Since CAD is a multifactorial disease, it is a highly interesting target for GWAS. Indeed, several GWAS in the context of CAD have been
performed over the last years by the Wellcome Trust Case Control Consortium, the Ottawa Heart study, the Myocardial Infarction Genetics
Consortium and others (Schunkert et al., 2011; Maouche and Schunkert, 2012). The first locus that was identified and could be replicated
in all CAD-related GWAS was a strong signal on chromosome 9p21 (Farouk et al., 2010). Another strong locus that has sparked particular
interest is on chromosome 10q11, close to the gene encoding CXCL12 (Farouk et al., 2010).
FIGURE 1 | Sequence similarities of different CXCL12/SDF-1 isoforms.
Six isoforms of CXCL12/SDF-1 have been described to date, which share a
common N-terminal amino acid sequence, but a distinct C-terminus. Shown
is the single letter amino acid code for all CXCL12 isoforms, with the shared
N-terminal sequence highlighted in green. Indications of specific amino acid
positions inform on the length of the different CXCL12 isoforms: α (89 aa), β
(93 aa), γ (119 aa), δ (140 aa), ε (90 aa), and φ (100 aa). aa, amino acid; SDF,
stromal cell-derived factor.
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intracellular calciummobilization through the activation of phos-
pholipase C (Teicher and Fricker, 2010). Furthermore, CXCL12
induces the recruitment of β-arrestin to CXCR4. This medi-
ates receptor desensitization through CXCR4 endocytosis (Orsini
et al., 1999), but also reduces CXCR4 coupling to Gαi signal-
ing, favoring β-arrestin-mediated MAPK activation. The latter
was particularly shown upon overexpression-induced dimeriza-
tion of CXCR4 with CXCR7, a chemokine receptor that will be
discussed in more detail below (Decaillot et al., 2011) (Figure 2).
Preferential signaling throughG-proteins vs. β-arrestin is not only
influenced through dimer formation of CXCR4 with CXCR7, but
also by the oligomerization state of CXCL12 (Drury et al., 2011;
Ray et al., 2012).
MIF AS AN ALTERNATIVE CHEMOKINE LIGAND FOR CXCR4
The CXCL12/CXCR4 axis was long considered a monogamous
relation, until in 2007 the chemokine MIF was surprisingly iden-
tified as an alternative ligand for CXCR4 (Bernhagen et al., 2007).
MIF is a ubiquitously expressed and highly conserved protein
of 114 aa (excluding the N-terminal methionine which is post-
translationally removed), with 90% homology between human
and mouse (Bernhagen et al., 1994). MIF plays an important role
in cell recruitment and arrest through binding to the chemokine
receptors CXCR2 and CXCR4 (Bernhagen et al., 2007). However,
it cannot be classified into one of the four typical chemokine
classes (C,CC,CXC,CX3C) due to the absence of a character-
istic cysteine motif in its N-terminus, and is therefore called
a chemokine-like function chemokine (Box 1). In contrast to
CXCL12, MIF is secreted in response to diverse inflammatory
stimuli, and has been associated with a clear pro-inflammatory
and pro-atherogenic role in multiple studies of patients and ani-
malmodels (Pan et al., 2004; Bernhagen et al., 2007). On the other
hand, MIF can also exert protective functions, as observed after
myocardial ischemia/reperfusion injury (MI/IRI) and in exper-
imental liver fibrosis. We will address the double-edged role of
MIF in myocardial ischemia below. For the involvement of MIF
in chronic atherosclerosis and injury-induced restenosis, we refer
to a recent review by Tillmann et al. (2013).
CXCR7, AN ALTERNATIVE RECEPTOR FOR CXCL12
HETERODIMERIZING WITH CXCR4
In 2005, CXCL12 was revealed to bind a second chemokine recep-
tor, named CXCR7 (or RDC1), with an even 10-fold higher
affinity compared with CXCR4 (Balabanian et al., 2005; Burns
et al., 2006). Similarly as CXCR4, CXCR7 is highly conserved
between human and mouse. Its deletion in mice is perina-
tally lethal and associated with defective cardiovascular devel-
opment (Sierro et al., 2007; Yu et al., 2011b). CXCR7 has been
FIGURE 2 | The CXCL12 signaling network. CXCL12 employs two distinct
receptors, CXCR4 and CXCR7. CXCR4 additionally acts a receptor for MIF,
whereas CXCR7 can also bind CXCL11. Generally, stimulation of CXCR4
triggers preferentially G-protein-coupled signaling, whereas activation of
CXCR7 or the CXCR4/CXCR7 complex induces β-arrestin-mediated
signaling. Internalization of the receptors CXCR4 and CXCR7, and
subsequent recycling to the cell membrane, is also mediated through
β-arrestin. Upon binding to CXCR7, CXCL12 is internalized and subjected to
lysosomal degradation. AKT, PKB, Protein kinase B; MAPK,
mitogen-activated protein kinase; MIF, macrophage migration inhibitory
factor; PI3K, phosphatidylinositide 3-kinase; Gαβγ, heterotrimeric G-protein
consisting of the subunits α, β, and γ.
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implicated in cell survival and adhesion (Burns et al., 2006)
and can mediate CXCL12-directed T-cell chemotaxis indepen-
dently from CXCR4 (Balabanian et al., 2005; Kumar et al., 2012).
Binding of the chemokine ligands CXCL12 and CXCL11 (also
called I-TAC) to CXCR7 enhances continuous CXCR7 inter-
nalization and delivery of the chemokine ligands to the lyso-
somes for degradation (Luker et al., 2010; Naumann et al.,
2010). Such CXCR7-mediated regulation of available CXCL12
concentrations has associated CXCR7 with a function as decoy
receptor, reducing acute CXCL12/CXCR4 signaling (Luker et al.,
2010). Furthermore, study of a CXCR7 agonist recently sug-
gested downregulation of CXCR4 protein levels by CXCR7 sig-
naling as another negative regulatory mechanism of CXCR7
toward the CXCL12/CXCR4 axis (Uto-Konomi et al., 2013).
Also, heterodimerization of CXCR7 with CXCR4 interferes with
CXCR4-induced Gαi protein-mediated signaling and favors β-
arrestin-linked signaling (Levoye et al., 2009; Decaillot et al.,
2011). On the other hand, the CXCL12 scavenging function of
CXCR7 can also positively influence CXCR4-mediated migration
by preventing the downregulation of CXCR4 surface expres-
sion and function through excessive CXCL12 concentrations
(Sanchez-Alcaniz et al., 2011). In addition to its modulatory
effect on CXCL12/CXCR4 signaling, CXCR7 is able to mediate
CXCL12-induced MAPK activation independently from CXCR4
(Wang et al., 2011). Although the precise signaling mechanisms
downstream of CXCR7 remain unclear, CXCR7 does not bind
to or induce the activation of heterotrimeric G-proteins as typ-
ical in classical GPCR signaling, but depends on ligand-induced
β-arrestin recruitment (Rajagopal et al., 2010) (Figure 2). This
atypical signaling explains why CXCR7 was recently renamed
atypical chemokine receptor (ACKR) 3 (Bachelerie et al., 2014).
As an important consideration, the widely used CXCR4
antagonist AMD3100 (Box 2) was recently revealed to be an
allosteric agonist of CXCR7, being able to induce the recruit-
ment of β-arrestin to CXCR7 at concentrations from 10μM. Also,
AMD3100 increased CXCL12 binding and CXCL12-triggered β-
arrestin recruitment to CXCR7 (Kalatskaya et al., 2009). The
CXCR4 antagonist TC14012 even showed a higher agonistic effect
on CXCR7 (Gravel et al., 2010). These findings, together with the
regulatory effects of CXCR7 on CXCL12/CXCR4 signaling, con-
siderably complicate the interpretation of all studies aiming to
dissect the molecular mechanisms and biological consequences of
specifically CXCL12/CXCR4 signaling.
THE CXCL12/CXCR4 AXIS MEDIATES HOMING AND
MOBILIZATION OF PROGENITOR CELLS
HOMING OF PROGENITOR CELLS IN THE BONE MARROW
In physiological conditions low numbers of hematopoietic stem
and progenitor cells (HSPCs) constantly circulate from the bone
marrow to the blood and back. The CXCL12/CXCR4 axis has
been shown to play a crucial role in the homing and retention
of HSPCs in the stem cell niches of the bone marrow (Mazo
et al., 2011). First, CXCL12 secreted by endothelial cells of sinu-
soids in the bone marrow may trigger firm arrest of rolling
CXCR4+ HSPCs through CXCR4-mediated integrin activation
(Peled et al., 2000; Mazo et al., 2011). After vascular extrava-
sation, HSPCs home into specialized bone marrow niches that
provide optimal conditions for HSPC survival, self-renewal, and
lineage differentiation and function (Jones and Wagers, 2008).
High expression of CXCL12 by bone marrow stromal cells con-
stitutes an important adhesive mechanism to retain CXCR4+
HSPCs in the bone marrow.
STRESS-INDUCED MOBILIZATION OF PROGENITOR CELLS
In conditions of stress or injury, HSPCs lose their anchorage in
these niches and are increasingly mobilized into the circulation
(Mazo et al., 2011). Interference with CXCL12/CXCR4-mediated
retention is an importantmechanism underlyingHSPCmobiliza-
tion. For example, granulocyte colony-stimulating factor (G-CSF
or CSF3), a mobilizing cytokine frequently used in the clinic,
reduces CXCL12 expression by bone marrow osteoblasts through
depletion of endosteal macrophages that support osteoblast func-
tion (Semerad et al., 2005; Winkler et al., 2010). Furthermore, G-
CSF has been associated with proteolytic inactivation of CXCR4
on HSPCs in the bone marrow (Levesque et al., 2003), despite
enhanced surface expression of CXCR4 on bone marrow cells
upon G-CSF treatment (Petit et al., 2002). In addition, G-
CSF-induced mobilization of HSPCs involves activity of the
protease dipeptidyl-peptidase 4 (DPP4, also known as CD26),
which inactivates CXCL12 through proteolysis (Christopherson
et al., 2003a,b; Campbell and Broxmeyer, 2008). A similar role
in CXCL12 destabilization during HSPC mobilization has been
suggested for the proteases matrix metallopeptidase (MMP) 9,
neutrophil elastase and cathepsin G. But although these proteases
are upregulated in the bone marrow upon treatment with G-CSF
(Levesque et al., 2002), combined inhibition of a broad range
of metalloproteinases and neutrophil serine proteases—including
MMP9, neutrophil elastase and cathepsin G—did not signifi-
cantly affect G-CSF-triggeredHSPCmobilization (Levesque et al.,
2004).
A fourth mechanism proposed to interfere with
CXCL12/CXCR4-mediated retention of HSPCs in the bone
marrow is an increased plasma level of CXCL12, which may
favor CXCL12-induced migration of HSPCs into the circulation
over their retention in the bone marrow. For example, increased
concentrations of CXCL12 in the blood due to injection of
CXCL12-expressing adenovirus or stabilized methionine-
CXCL12 induced the mobilization of hematopoietic cells and
progenitors (Hattori et al., 2001; Moore et al., 2001). However, it
has been debated whether this is indeed due to CXCL12-induced
mobilization, or rather to a reduced CXCL12/CXCR4-mediated
retention of these cells in the bone marrow caused by CXCL12-
induced downregulation of CXCR4 on their cell surface (Bonig
and Papayannopoulou, 2012). Similarly, it is still debated
whether the mobilization of HSPCs by CXCR4 antagonists, as
was recently discussed in detail (Rettig et al., 2012), is mostly
the result of a direct blockade of CXCR4 on HSPCs in the bone
marrow interfering with CXCR4-mediated homing (Karpova
et al., 2013), or whether these antagonists may also mediate
HSPC egress by altering the CXCL12 gradient in favor of mobi-
lization. In context of the latter, it was shown that treatment
with the CXCR4 antagonist AMD3100 induces a fast release of
CXCL12 from bone marrow stroma to the circulation, which
may favor CXCL12/CXCR4-mediated mobilization of HSPCs
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into circulation over their anchorage in bone marrow niches (Dar
et al., 2011).
Clearly, the CXCL12/CXCR4 axis plays a pivotal but complex
role in the homing and mobilization of progenitor cells, and an
intertwinement with different other pathways even further com-
plicates the picture. For example, AMD3100-induced progenitor
cell mobilization was recently shown to require the expression of
MMP9 and endothelial nitric oxide synthase (eNOS, also known
as NOS3) in bone marrow-derived cells (Jujo et al., 2010, 2013).
Also, CXCL12-mediated homing and mobilization of progenitor
cells is modulated by e.g., fms-related tyrosine kinase 3 (FLT3)
ligand (Fukuda et al., 2005), transforming growth factor (TGF)
β (Basu and Broxmeyer, 2005), and CCR5 chemokine receptor
ligands (Basu and Broxmeyer, 2009).
SURVIVAL AND PROLIFERATION OF PROGENITOR CELLS
In addition to homing and mobilization, the CXCL12/CXCR4
axis provides important survival and proliferative signals to pro-
genitor cells (Lataillade et al., 2000; Lee et al., 2002; Broxmeyer
et al., 2003a,b; Guo et al., 2005). Together, these functions under-
lie to a considerable extent the currently known involvement of
the CXCL12/CXCR4 axis in CAD, as will be discussed in detail
below.
THE CXCL12/CXCR4 AXIS IN CAD: IDENTIFYING POTENTIAL
FUNCTIONS AND UNDERLYING MECHANISMS FROM IN
VITRO, ANIMAL AND PATIENT OBSERVATIONS
The involvement of CXCR4 and its ligand CXCL12 in injury-
induced restenosis and MI has mostly been linked to progenitor
cell recruitment. In contrast, the role of the CXCL12/CXCR4
axis in native atherosclerosis remains largely unclear, with mostly
only in vitro studies shedding some light on the effect of CXCR4
signaling on cell type-specific functions relevant in atherogen-
esis. Here, we aim to provide an overview of in vitro, animal
and patient observations that may provide insight into the (cell
type-specific) effects of CXCR4 signaling on native atheroscle-
rosis, injury-induced restenosis and MI (Table 1, Supplemental
Table 1).
CXCR4 IN MYOCARDIAL ISCHEMIA
Protective effects through cardiomyocyte protection and progenitor
cell recruitment
CXCR4 and its ligand CXCL12 are expressed in cardiac myocytes
and fibroblasts, and myocardial ischemia significantly upregu-
lates CXCL12 (Pillarisetti and Gupta, 2001; Yamani et al., 2005;
Hu et al., 2007). Different studies have revealed a protective
role for CXCL12/CXCR4 signaling after MI and MI/IRI through
survival effects on resident cardiomyocytes and recruitment of
protective circulating cells. Intracardiac or intramyocardial injec-
tion of CXCL12 reduced infarction size and increased cardiac
function after MI/IRI (Hu et al., 2007) and MI (Segers et al.,
2007; Saxena et al., 2008), and cardioprotective effects were
blocked with AMD3100 (Hu et al., 2007). CXCL12-induced car-
dioprotection was associated with improved survival of hypoxic
myocardium and increased neo-angiogenesis, and was linked
with anti-apoptotic AKT (also known as PKB = protein kinase
B) and MAPK3/1 (also known as ERK1/2) signaling in cardiac
Table 1 | The CXCL12/CXCR4 axis in CAD.
CXCL12/CXCR4 IN MYOCARDIAL ISCHEMIA
Expression
CXCL12 and CXCR4 expressed in cardiac
myocytes, fibroblasts and cardiac ECs
Hu et al., 2007; Saxena et al.,
2008
Myocardial ischemia increases CXCL12
expression
Pillarisetti and Gupta, 2001;
Yamani et al., 2005; Hu et al.,
2007
Cardioprotective effects of CXCL12/CXCR4 signaling
Reduced infarction size and increased
cardiac function upon CXCL12 delivery
after MI/IRI and MI
Hu et al., 2007; Segers et al.,
2007; Saxena et al., 2008
Associated with:




Saxena et al., 2008
Enhanced incorporation of progenitor
cells in infarcted region
Abbott et al., 2004;
Elmadbouh et al., 2007;
Segers et al., 2007; Purcell
et al., 2012
Cardioprotective signaling through AKT
and ERK
Hu et al., 2007; Saxena et al.,
2008
Enhanced VEGF expression Saxena et al., 2008
Cardiovascular detrimental effects of CXCR4 signaling
Inflammatory cell infiltration Chen et al., 2010a; Liehn
et al., 2011
Enhanced TNFα expression and
cardiomyocyte apoptosis
Chen et al., 2010a
Contrasting effects of CXCR4 antagonist AMD3100
Single treatment: cardioprotective after
MI/IRI and MI
Jujo et al., 2010, 2013
Enhanced incorporation of progenitor
cells in infarcted region
Increased neo-vascularization
Daily treatment: cardioprotective after MI Proulx et al., 2007
Continuous administration: reduced
cardiac function and survival after MI
Dai et al., 2010; Jujo et al.,
2010
Reduced incorporation of progenitor
cells in the infarcted region despite
enhanced mobilization
Jujo et al., 2010
Increased proliferation of resident
cardiac progenitor cells (⇒ reduced
differentiation?)
Dai et al., 2010
CXCL12/CXCR4 IN INJURY-INDUCED RESTENOSIS (WIRE INJURY
OF CAROTID ARTERY)
Expression
Vascular injury increases CXCL12
expression in plasma and vascular wall
Schober et al., 2003; Yin
et al., 2010
Injury-induced CXCL12 upregulation in
the vascular wall is mediated through:
HIF1α upregulation Karshovska et al., 2007
Apoptosis in injured artery Zernecke et al., 2005
(Continued)
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Table 1 | Continued
Detrimental effects of CXCL12/CXCR4 signaling
Apoe−/− treated with CXCL12 blocking
antibody
Schober et al., 2003;
Zernecke et al., 2005
Reduced neointimal lesion size
Reduced SMC content and reduced
mobilization of Lin−Sca1+ cells
Apoe−/− transplanted with Cxcr4−/−
bone marrow or treated locally with
lentivirus expressing mutant CXCL12
(antagonist)
Zernecke et al., 2005
Reduced neointimal lesion size
Reduced SMC content
No effect on reendothelialization
Apoe−/− treated with CXCR4 antagonist
AMD3465
Karshovska et al., 2008
Reduced neointimal lesion size
Reduced SMC content and
mobilization of Lin−Sca1+ cells
Reduced neointimal proliferation
No effect on reendothelialization
Apoe−/− treated with CXCR4 antagonist
POL5551
Hamesch et al., 2012
Reduced neointimal lesion size
Reduced SMC content and
mobilization of Lin−Sca1+ cells
Variable effect on macrophage content
and reendothelialization depending on
treatment regime
Protective effects of CXCL12/CXCR4 signaling
Apoe−/− injected with EPCs Hristov et al., 2007
Blocking CXCR2 or CXCR4 on EPCs
reduced adhesion to injured artery
C57BL/6 injected with EPCs Yin et al., 2010
Enhanced reendothelialization and
reduced neointimal lesion size with
wild-type but not CXCR4-blocked EPCs
C57BL/6 treated with Cxcl12 blocking
antibody
Yin et al., 2010
Reduced mobilization of EPCs
(Sca1+Flk1+ cells)
Reduced reendothelialization
No effect on neointimal lesion size
C57BL/6 injected with Foxc2-transgenic
EPCs
Li et al., 2011
Prior CXCR4 blockade on EPCs
reduced their adhesion to the injured
artery and reduced their protective
effect on neointimal lesion size
NRMInu/nu athymic nude mice injected
with CXCR4-transgenic EPCs
Chen et al., 2010b
Enhanced reendothelialization
compared to infusion of wild-type
EPCs
(Continued)
Table 1 | Continued
CXCL12/CXCR4 IN CHRONIC ATHEROSCLEROSIS
Protective effects of CXCL12/CXCR4 signaling
Apoe−/− treated with endothelial
apoptotic bodies (high-fat diet study)
Zernecke et al., 2009
Reduced lesion size, macrophage
content and apoptosis
Effect of apoptotic bodies reversed
upon treatment with AMD3100
Possible detrimental effects of CXCL12/CXCR4 signaling
Apoe−/− with established
atherosclerosis, treated with conjugated
linoleic acid (CLA)
De Gaetano et al., 2013
CLA induced lesion regression
Associated with reduced CXCR4
expression and CXCL12-induced
chemotaxis of monocytes
Apoe−/− treated with H2S donor
GYY4137
Liu et al., 2013
Reduced lesion size
Associated with reduced CXCR4
expression on macrophages
Studies without effects of CXCL12/CXCR4 signaling
Apoe−/− treated with CXCL12
neutralizing antibody during last 4 weeks
of 12-weeks high-fat diet
Bernhagen et al., 2007
No effect on lesion size
Contrasting effects of CXCR4 antagonists
Apoe−/− treated with CXCR4 antagonist
AMD3465
Zernecke et al., 2008
Enhanced mobilization of Lin−Sca1+
cells and leukocytes, predominantly
neutrophils
Increased lesion size with reduced
SMC content, but increased neutrophil
content
Increased apoptosis of plaque cells
“Reversa” mouse treated with
AMD3100 (high-fat diet study)
Yao et al., 2012
Enhanced mobilization of progenitor
cells, including “EPCs” (Cd11b− cKit+
Flk1+ or Cd34+Cd133+Flk1+)
Enhanced atherosclerosis regression
after plasma lipid normalization
CXCL12/CXCR4 IN PARTIAL LIGATION MODEL (ACCELERATED
ATHEROSCLEROSIS MODEL)
Protective effects of CXCL12/CXCR4 signaling
Apoe−/− with systemic CXCL12
treatment
Akhtar et al., 2013
Enhanced recruitment and
incorporation of bone marrow-derived
Lin−Sca1+ cells
(Continued)
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Table 1 | Continued
Enhanced lesion stability, without
effect on lesion size
Reduced macrophage content
Apoe−/− with local CXCL12 siRNA
treatment
Akhtar et al., 2013
Increased lesion size




SNPs rs1746048 (risk allele: C) and
rs501120 (risk allele: T) on Chr10q11.21,
80 Kb downstream of CXCL12
Significantly associated with CAD and
MI risk
Burton et al., 2007; Samani
et al., 2007; Kathiresan et al.,
2009; Schunkert et al., 2011
Although genome-wide significance
could not be reached in 2 other studies




Significantly reduced CXCL12 plasma
levels in patients with angina,
especially in unstable angina
Damas et al., 2002
CAD risk genotype rs501120 (T/T)
significantly associated with reduced
CXCL12 plasma levels
Kiechl et al., 2010
CXCL12 progressive?
Risk alleles of rs1746048 and rs501120
significantly associated with higher
CXCL12 plasma levels
Mehta et al., 2011
CXCR4 expression
Patients with angina show reduced
CXCR4 surface expression on peripheral
blood cells
Damas et al., 2002
myocytes and endothelial cells (Hu et al., 2007; Saxena et al.,
2008). Also, delivery of CXCL12 triggered upregulation of vas-
cular endothelial growth factor (VEGF) in the infarcted area
and in cardiac endothelial cells, with VEGF an important reg-
ulator of angiogenesis and progenitor cell recruitment (Saxena
et al., 2008). Furthermore, multiple studies have explored the
effect of CXCL12 delivery into the myocardium through local
treatment with CXCL12-overexpressing adenovirus, CXCL12-
transgenic skeletal myoblasts or CXCL12-releasing hydrogels.
Such exogenous CXCL12 delivery was associated with enhanced
recruitment and incorporation of CXCR4+ stem and progenitor
cells in the infarcted area (Abbott et al., 2004; Elmadbouh et al.,
2007; Segers et al., 2007; Purcell et al., 2012).
Stem cell transplantation during MI seems promising to
improve cardiac outcome (Sanganalmath and Bolli, 2013), but
it is debated whether this is primarily mediated through direct
regeneration of cardiac myocytes or through protective paracrine
effects on remodeling or preservation of injured tissue (Liehn
et al., 2013b). For example, transplantation of endothelial
progenitor cells (EPCs) was associated with increased neovascu-
larization and improved cardiac function after MI and MI/IRI,
despite variable effects on inflammation and apoptosis (Schuh
et al., 2008, 2012). Overexpression of CXCL12 in transplanted
EPCs further increased angiogenesis, however without signifi-
cant improvement of cardiac function (Schuh et al., 2012). In a
complementary approach, transplantation of mesenchymal stem
cells (MSCs), which have been described as cardiac precursors, is
widely investigated as a potential therapy after MI (Hatzistergos
et al., 2010; Dong et al., 2012; Liehn et al., 2013b). Overexpression
of CXCL12 in transplanted MSCs improved survival of car-
diomyocytes after MI, however without evidence for cardiac
regeneration (Zhang et al., 2007). MSCs with transgenic CXCR4
expression displayed increased incorporation into the ischemic
area, which was associated with increased angiogenesis, myogen-
esis and cardiac function (Zhang et al., 2008; Huang et al., 2012).
In vitro experiments demonstrated hypoxia to increase CXCR4
expression on MSCs, and CXCR4-mediated migration of MSCs
to CXCL12 was shown to require PI3K/AKT signaling (Yu et al.,
2010). The CXCL12/CXCR4 axis was also at least partly respon-
sible for the beneficial effects of VEGF-overexpressing MSCs by
mediating the recruitment of cardiac stem cells to the infarcted
region (Tang et al., 2011). Furthermore, cardioprotective effects
of transplanted MSCs were shown to require myocardial CXCR4
expression (Dong et al., 2012).
The efficiency of AMD3100 in mobilizing progenitor cells,
including EPCs, from the bone marrow was associated with
enhanced accumulation of progenitor cells in the infarcted tis-
sue, enhanced neovascularization and improved cardiac func-
tion after single AMD3100 treatment in an MI and MI/IRI
model (Jujo et al., 2010, 2013). Similarly, cardioprotective effects
were reported of daily AMD3100 injections after MI in rats
(Proulx et al., 2007). However, two independent groups revealed
a reduced cardiac outcome after MI upon chronic AMD3100
administration (Dai et al., 2010; Jujo et al., 2010). This was
either associated with a reduced incorporation of progenitor
cells in the infarcted region despite enhanced mobilization (Jujo
et al., 2010), or with an increased proliferation of resident car-
diac progenitor cells. This latter observation raised the suggestion
whether increased proliferation may be linked to reduced dif-
ferentiation, so whether cardioprotective CXCR4 signaling may
be required to direct cardiac progenitors to cardiac commitment
to ensure their participation in repair of injured myocardium
(Dai et al., 2010).
Interestingly, platelet-surface binding of CXCL12, which cor-
related with platelet activation, was significantly increased in
patients with acute coronary syndrome (ACS) compared to
patients with stable angina pectoris, and correlated with the num-
ber of circulating hematopoietic progenitor cells (Stellos et al.,
2009). Similarly, surface expression of CXCR7 but not CXCR4was
found to be significantly enhanced on platelets from patients with
ACS compared to subjects with stable CAD (Rath et al., 2014).
These data may be supported by recent findings that CXCL12
upregulates CXCR7 surface availability on platelets (Chatterjee
et al., 2014), as will be discussed in more detail later. Of note,
platelet CXCR7 surface expression levels above average in patients
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with ACS positively correlated with an increase in the left ventric-
ular ejection fraction as ameasure of recovery afterMI, suggesting
a beneficial effect of CXCL12/CXCR7 signaling on functional
recovery in ACS patients (Rath et al., 2014).
Double-edged role of CXCR4 in the ischemic heart
Despite cardioprotective functions of the CXCL12/CXCR4 axis
in the ischemic heart, Cxcr4-heterozygosity in mice reduced
infarct size after MI, however without affecting cardiac func-
tion. This was explained by a counterbalance of on the one
hand reduced neovascularization, and on the other hand reduced
inflammation with less neutrophils and a preferential recruitment
of Gr1low over inflammatory Gr1high monocytes (Liehn et al.,
2011). Likewise, adenovirus-mediated overexpression of CXCR4
in the heart increased infarct size and reduced cardiac function.
This was associated with an enhanced recruitment of inflamma-
tory cells, enhanced tumor necrosis factor (TNF) α expression
and increased apoptosis of cardiomyocytes (Chen et al., 2010a).
On the other hand, deficiency of Cxcr4 specifically in cardiac
myocytes did not affect heart function or remodeling after MI
(Agarwal et al., 2010).
Together, these studies demonstrate a double-edged role of
CXCR4 in the ischemic heart, and require further investigation
of the role of CXCR4 and its chemokine ligands in the inflam-
matory processes associated with MI. In this context, also the
alternative CXCR4 ligand MIF is upregulated in myocardium and
plasma after MI (Yu et al., 2001, 2003) and can exert cardio-
protection. Underlying mechanisms include activation of AMP-
activated protein kinase (AMPK) (Miller et al., 2008), reduction
of oxidative stress (Koga et al., 2011) or inhibition of c-Jun
N-terminal kinase (JNK)-mediated apoptosis (Qi et al., 2009).
An important role for the chemokine receptor CXCR2 on resi-
dent cardiac cells in MIF-mediated myocardial protection after
ischemic injury was recently shown (Liehn et al., 2013a), but
it remains unclear whether also MIF/CXCR4 signaling in car-
diomyocytes may contribute to cardioprotection. Furthermore,
MIF-induced recruitment and differentiation of protective EPCs
through CXCR4 and CXCR2may be involved in the cardioprotec-
tive effects of MIF (Simons et al., 2011; Asare et al., 2013; Kanzler
et al., 2013). On the other hand, adverse effects of MIF through
myocardial infiltration of inflammatory cells were revealed after
prolonged ischemic injury in both MI and MI/IRI (Gao et al.,
2011; White et al., 2013). Although these studies did not examine
which MIF receptor was involved, a recent report demonstrated
an important role for CXCR2 in mediating MIF-triggered mono-
cyte recruitment in the ischemic heart (Liehn et al., 2013a). But
also here, an additional involvement of MIF/CXCR4 interaction
in ischemic inflammatory cell recruitment remains unclear. In
conclusion, recent data indicate that similarly as CXCR4, MIF
plays a double-edged role in myocardial ischemia. However, the
relative importance of CXCR4 vs. other MIF receptors as CXCR2,
in MIF-mediated effects remain unclear.
CXCR4 IN ARTERIAL INJURY-INDUCED RESTENOSIS
The CXCL12/CXCR4 axis has been revealed to contribute to
injury-induced restenosis, which is a major problem after coro-
nary revascularization. CXCL12 expression is increased after
vascular injury through enhanced hypoxia-inducible factor (HIF)
1α expression (Schober et al., 2003; Karshovska et al., 2007)
and is preceded and mediated by apoptosis in the injured ves-
sel wall (Zernecke et al., 2005). Systemic treatment of mice with
a CXCL12 blocking antibody or a CXCR4 antagonist reduced
injury-induced neointimal size and content of smooth muscle
cells (SMCs), which are a driving force of neointimal hyperplasia.
Similar results were obtained after transplantation with Cxcr4−/−
bone marrow or local treatment with a dysfunctional CXCL12
mutant (Schober et al., 2003; Zernecke et al., 2005; Karshovska
et al., 2008; Hamesch et al., 2012). In these studies reduced SMC
content was associated with a reduction in injury-induced mobi-
lization of Lin−Sca1+ progenitor cells, which were shown to be
incorporated into neointimal lesions and capable to differentiate
into SMCs (Schober et al., 2003; Zernecke et al., 2005). This cor-
responded with previous observations that bone marrow-derived
cells can be recruited to mechanically injured arteries, where
they can differentiate into vascular SMCs (VSMCs) and even
endothelial cells (ECs) (Sata et al., 2002; Tanaka and Sata, 2008).
Multiple studies have linked EPCs with enhanced reendothe-
lialization and reduced neointimal hyperplasia after vessel injury
(Werner et al., 2003; Kong et al., 2004). CXCR4 was shown
to contribute to adhesion of in vitro mononuclear cell-derived
EPCs to injured arteries, although to a lesser extent than CXCR2
(Hristov et al., 2007). Whereas CXCR4 blockade interfered with
the capacity of infused EPCs to promote reendothelialization
and reduce neointimal lesion size after carotid artery injury (Yin
et al., 2010; Li et al., 2011), overexpression of CXCR4 promoted
CXCL12-triggered migration and adhesion of EPCs in vitro and
enhanced their capacity to promote endothelial recovery after
vascular denudation in vivo (Chen et al., 2010b). However,
it remains debated whether EPCs really affect injury-induced
restenosis through direct incorporation in the injured vascular
wall, or rather through paracrine effects on resident vascular cells
by secreting mitogenic cytokines and growth factors as VEGF
(Yoshioka et al., 2006; Iwata et al., 2010; Nemenoff et al., 2011;
Hagensen et al., 2012; Merkulova-Rainon et al., 2012).
Furthermore, blockade of CXCR4 was shown to reduce cel-
lular proliferation and the macrophage content of neointimal
lesions after femoral artery injury, which was associated with
reduced neointimal lesion size (Olive et al., 2008). In the same
mouse model, ability of macrophage colony stimulating factor
(M-CSF or CSF1) to accelerate injury-induced neointimal hyper-
plasia was abolished upon treatment with AMD3100. This was
associated with reduced lesional incorporation of CXCR4+ cells
despite enhanced white blood cell count in the peripheral blood,
suggesting a detrimental role for CXCR4 in injury-induced neoin-
timal hyperplasia in mediating the recruitment of inflammatory
cells into neointimal lesions (Shiba et al., 2007).
In conclusion, blocking the CXCL12/CXCR4 axis interferes
with injury-induced neointimal hyperplasia through reduced
recruitment of CXCR4+ smooth muscle progenitors and inflam-
matory cells to the site of injury. On the other hand, CXCR4
enhances the ability of infused EPCs to adhere to injured ves-
sels and promote reendothelialization. Although these data derive
from in vitro cultured EPCs, which may behave different than the
rather vaguely defined “circulating EPCs” (Steinmetz et al., 2010;
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Rennert et al., 2012), the current findings suggest a double-edged
role for CXCR4 in injury-induced restenosis through recruitment
of (progenitor) cells that either stimulate or interfere with neoin-
timal hyperplasia. Such double-edged function was recently also
observed upon tamoxifen-induced endothelial-specific deficiency
of Cxcr4 (Cxcr4EC−KO)in apolipoprotein E-deficient (Apoe−/−)
mice, which significantly decreased mobilization of both circu-
lating Sca1+Flk1+Cd31+ cells, often referred to as EPCs, and of
Lin−Sca1+ cells upon wire-mediated injury of the carotid artery.
Furthermore, Cxcr4EC−KO Apoe−/− mice showed a reduced reen-
dothelialization efficiency, which was linked with a decrease in
endothelial wound healing and in vivo proliferation. As a net
result, endothelial-specific Cxcr4 deficiency triggered the for-
mation of larger neointimal lesions, displaying an increase in
inflammatory macrophages but a reduced SMC content (Noels
et al., 2014). Whether CXCR4 signaling also affects specific func-
tions of VSMCs or macrophages in context of vascular injury
remains to be investigated.
CXCR4 IN NATIVE ATHEROSCLEROSIS: PROGENITOR CELL
MOBILIZATION
Vascular progenitor cells
In contrast to conditions of MI and injury-induced resteno-
sis, not much is known about a potential involvement of bone
marrow-derived vascular progenitor cells in native atherosclero-
sis, as has been recently summarized for EPCs (Du et al., 2012)
and vascular smooth muscle progenitor cells (SPCs) (Merkulova-
Rainon et al., 2012). It was shown that infusion of EPCs as well
as treatment with AMD3100, which triggered EPC mobilization,
enhanced plaque regression after normalization of plasma lipid
levels in Reversa mice (Yao et al., 2012). In contrast, a study in
Apoe−/− mice did not reveal an atheroprotective effect of systemic
AMD3100 treatment, but rather found AMD3100 to abolish ben-
eficial effects of apoptotic body treatment on atherosclerosis.
Endothelial apoptotic bodies were shown to contain miRNA126,
which is transferred to neighboring ECs to induce the expression
and release of CXCL12 by unleashing autoregulatory CXCR4 sig-
naling. Injection of EC-derived apoptotic bodies into Apoe−/−
mice increased CXCL12 expression in atherosclerotic lesions and
promoted progenitor cell mobilization and their recruitment to
the endothelial lining of the lesions. Lesions of mice treated with
apoptotic bodies were generally smaller in size and exhibited
a less inflammatory phenotype with reduced macrophage and
apoptotic cell content (Zernecke et al., 2009). Thus, despite con-
tradictory findings on the effect of AMD3100 treatment, both
studies suggest an atheroprotective function for CXCL12/CXCR4
signaling through mobilization of protective EPCs. Interestingly,
it was revealed that patients with CAD show lower levels and
a decreased migratory response of circulating EPCs (Vasa et al.,
2001). In addition, systemic treatment of mice with CXCL12 in a
partial ligation model—which induces advanced atherosclerotic
lesions with an unstable phenotype—enhanced the recruitment
of Lin−Sca1+ SPCs and promoted a more stable plaque pheno-
type (Akhtar et al., 2013). Such plaque-stabilizing role for SPCs
was also suggested earlier by Zoll et al, who showed that injec-
tion of SPCs reduced atherosclerotic lesion size and improved
lesion stability (Zoll et al., 2008). Together, these studies reveal an
atheroprotective function for CXCL12/CXCR4 signaling through
recruitment of protective EPCs and plaque-stabilizing SPCs.
However, others reported on an atheroprogressive role for vas-
cular progenitor cells. Inducing apoptosis of rare lesional bone
marrow-derived SMCs substantially decreased plaque size (Yu
et al., 2011a), and George et al. found EPC transfer to increase
atherosclerosis in mice (George et al., 2005). Contradictory find-
ings on the presence or function of vascular progenitor cells
in chronic atherosclerosis may be related to the atherosclerosis
model, lesion stage, but also on the vague definition of such pro-
genitor cells. Further research is definitively needed to improve
phenotypical and functional characterization of vascular pro-
genitor cell subsets in context of atherosclerosis before a role
of the CXCR4/CXCL12 axis in their mobilization and potential
functions in this pathology can be investigated in detail.
Hematopoietic progenitor cells
Interestingly, MI was recently revealed to accelerate atheroscle-
rosis in mice. MI reduced CXCL12 expression in bone mar-
row through sympathetic nervous system activity and signaling
through β3 adrenergic receptor (β3AR or ADRB3). In this way,
MI enhanced mobilization of HSPCs from bone marrow niches
and their hosting in the spleen, triggering myelopoiesis and
increased atherosclerosis up to 3 months after coronary ligation
(Dutta et al., 2012). Although the latter study did not address
the underlying mechanisms of CXCL12 upregulation upon β3AR
blocking nor examine potential effects on CXCR4 expression or
function, LaRocca et al. revealed a direct (physical) interaction of
β2 adrenergic receptors with CXCR4 resulting in the modifica-
tion of the contractile nature of cardiomyocytes (Larocca et al.,
2010). It is further known that β2- and β3 adrenergic recep-
tors cooperate during progenitor cell mobilization with partial
functional redundancy under stress (Mendez-Ferrer et al., 2010).
Hence, one may speculate that Cxcr4 may also functionally inter-
act with other adrenergic receptors, like β3AR, in a direct or
indirect way.
CXCR4 IN NATIVE ATHEROSCLEROSIS: CELL TYPE-SPECIFIC
FUNCTIONS?
In addition to a role for CXCR4 through progenitor cell mobi-
lization, CXCR4 may affect native atherogenesis by modifying
atherosclerosis-relevant cellular functions. CXCR4 expression has
been described on many cell types including monocytes and
macrophages, neutrophils (Bruhl et al., 2003), T-cells (Murphy
et al., 2000), B-cells (Nie et al., 2004), mature ECs (Gupta et al.,
1998), and SMCs (Nemenoff et al., 2008; Jie et al., 2010). All of
these cells play distinct roles in the pathophysiology of atheroscle-
rosis, but not much is known about the precise role of CXCR4 in
individual cellular responses.
Monocytes and macrophages
Monocytes and macrophages have been proven to be of out-
standing importance in the progression and development of
mature atherosclerotic lesions and their depletion has been rec-
ognized atheroprotective already 20 years ago (Ylitalo et al.,
1994). As the picture grows it becomes more and more evi-
dent that depletion of individual cell subsets does not serve as
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a realistic therapeutic approach, hence understanding the details
of cell–cell interactions and communication gains importance
(Weber and Noels, 2011).
CXCR4 expression and potential functions: studies of human cells
Macrophages and foam cells. CXCR4 is expressed on all monocyte
subsets, with highest expression on classical human monocytes.
This contrasts with observations in mice, which show high-
est CXCR4 levels on non-classical monocytes (Ingersoll et al.,
2010), as will be discussed later in more detail. Gupta et al.
revealed high expression of CXCR4 on human blood monocytes,
which declined while they differentiated into macrophages, but
restored again after 24 h, peaking at 7 days. Interestingly, CXCR4
expression onmacrophages could be further upregulated by stim-
ulation with oxidized low-density lipoprotein (oxLDL). From
here the authors conclude that, although there is no direct evi-
dence, restoration of CXCR4 expression on lesional macrophages
and its further up-regulation by oxLDL during foam cell for-
mation may contribute to migration of intimal foam cells and
the subsequent progression of plaque growth (Gupta et al.,
1999). Furthermore, CXCL12/CXCR4 signaling was linked with
enhanced macropinocytosis in leukocytes (Tanaka et al., 2012),
suggesting that a lack of CXCR4 may also influence (modified)
lipid accumulation in macrophages and other lesional cells. In
contrast, a recent study found CXCL12 to induce phagocytosis
and the uptake of acetylated LDL in THP1-derived macrophages
specifically through binding CXCR7 but not CXCR4 (Ma et al.,
2013). In this context, the CXCR7 agonist CCX771 was recently
shown to increase the uptake of very low-density LDL (VLDL)
in adipocytes. Correspondingly, treatment of Apoe−/− mice with
CCX771 reduced the levels of circulating VLDL and decreased
atherosclerosis (Li et al., 2014). Whether similar mechanisms
can be identified in other cell types as macrophages remains to
be examined, as are the exact mechanisms underlying CXCR7-
mediated uptake of VLDL or modified lipids.
Patients with CAD. In patients with stable and unstable angina
pectoris CXCR4 surface expression on peripheral bloodmononu-
clear cells (PBMCs) was decreased and CXCL12 levels in patients
with unstable angina pectoris were explicitly low. However,
in vitro treatment of PBMCs from these patients with high
concentrations of CXCL12 reduced mRNA and protein levels
of chemokine ligands CCL2 and CXCL8, MMP9 and tissue
factor, while increasing tissue inhibitor of metalloproteinases
(TIMP) 1. Therefore, high (local) concentrations of CXCL12
may mediate anti-inflammatory and matrix-stabilizing effects
promoting plaque stabilization and may be beneficial in angina
pectoris and ACSs (Damas et al., 2002). Another study showed
autocrine CXCL12 signaling to downregulate expression of
runt-related transcription factor (RUNX) 3 in human mono-
cytes/macrophages, thereby promoting a pro-angiogenic, but
immunosuppressive phenotype of these cells (Sanchez-Martin
et al., 2011).
Compounds regulating CXCR4. Several compounds were iden-
tified to modify CXCR4-mediated immune responses in vitro.
Glucocorticoids have been demonstrated to upregulate CXCR4
expression on human bloodmonocytes and Caulfied et al. assume
that increased CXCR4 expression sensitizes monocytes to tissue
resident CXCL12, guiding monocytes away from sites of inflam-
mation with supposingly lesser local CXCL12 release (Caulfield
et al., 2002). The latter most likely contradicts another study,
which revealed high expression of CXCL12 in SMCs, ECs and
macrophages in human atherosclerotic plaques but not in normal
vessels (Abi-Younes et al., 2000). This would rather argue for a
chemotactic gradient of CXCL12 toward the site of inflammation,
although this might be disease- and cell type-dependent.
As a second example, monocyte CXCR4 expression has been
shown to be modulated by hydrogen sulfide (H2S) donors. H2S
donors have lately been recognized as vasoprotective agents and
changes in H2S may affect atherosclerosis. Interestingly, a syn-
thetic slow H2S releaser (GYY4137) inhibited oxLDL-induced
foam cell formation and cholesterol esterification in RAW264
cells and primary human monocytes, which was accompanied
by decreased CXCR4 expression (Liu et al., 2013). In con-
trast, angiotensin-converting enzyme (ACE) inhibitors, widely
used to treat high blood pressure by interfering with the renin-
angiotensin system, did not affect CXCR4 expression on primary
human monocytes and THP1 cells (Apostolakis et al., 2007). The
same group also assessed if angiotensin I and II treatment would
have a direct impact on chemokine receptor expression on THP1
cells, again CXCR4 expression was not altered (Apostolakis et al.,
2010).
Conjugated linoleic acids (CLA) were shown to influence
human peripheral blood monocyte function by suppressing
CD18 expression, thereby reducing the number of β2-integrins
expressed on the external surface and decreasing adhesion to acti-
vated ECs. In addition, CLA reduced CXCR4 expression, resulting
in an only minor initiation of “inside out” signaling. As a result,
partial, but incomplete, activation of β2-integrins further reduces
adherence of leukocytes and their migration to CXCL12 (De
Gaetano et al., 2013).
Statins, which lower intracellular cholesterol synthesis, are
the gold standard to treat hyperlipidemia-associated atheroscle-
rosis, but have also been reported to cause numerous other
pleiotropic effects. To examine if statin withdrawal would affect
human monocyte subsets in patients with stable CAD, statin
treatment was cut off for 2 weeks. Subsequent evaluation of
blood monocyte subsets did not reveal any differences in num-
bers, but downregulation of Toll-like receptor (TLR) 4 on all
subsets and decreased expression of CXCR4 on classical mono-
cytes (CD14++ CD16−) (Jaipersad et al., 2013). Interestingly,
high doses of statin treatment were also shown to reduce gen-
eral CXCL12 plasma levels in hyperlipidemic patients (Camnitz
et al., 2012). However, it remains elusive whether statin treatment
and a subsequent increase in CXCR4 expression, but decreased
CXCL12 titers, point at a direct pro- or anti-atherosclerotic role
of the CXCL12/CXCR4 axis.
Another mechanism, recently recognized to drive atheroscle-
rotic lesion growth, is hypoxia (Marsch et al., 2013). Notably,
hypoxia-induced upregulation of the transcriptional activator
HIF1 triggers CXCR4 mRNA and protein expression in human
monocytes. In addition, these cells showed increased migra-
tion toward CXCL12 under hypoxic conditions. Based on these
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findings the authors conclude that the hypoxia–HIF1–CXCR4
pathway may regulate cell trafficking and localization into
hypoxic tissues, such as atherosclerotic lesions (Schioppa et al.,
2003).
In contrast, CXCR4 expression on macrophages was sup-
pressed in the presence of M-CSF. Increased M-CSF titers have
been implicated in the pathogenesis of atherosclerosis and it was
shown that M-CSF delivers a pro-atherogenic signal to human
macrophages by stimulation of cholesterol accumulation and
pro-inflammatory chemokine secretion. Thus, M-CSF-induced
suppression of macrophage CXCR4 expression may point at an
atheroprotective function of downstreamCXCR4 signaling events
(Irvine et al., 2009).
CXCR4 expression and potential functions: mouse studies. The
above-mentioned studies on humanmonocytes andmacrophages
suggest diverse potential roles for CXCR4 in atherosclerosis, still
mouse studies are equally elusive, without a clear indication for a
pro- or anti-atherogenic role for CXCL12/CXCR4. In contrast to
human monocytes, CXCR4 in mouse is higher expressed on non-
classical monocytes and it is not clear if this does necessarily imply
functional differences in individual mouse and human monocyte
subsets or not (Ingersoll et al., 2010).
One study reported an interesting finding using a mutant
non-heparin sulfate-binding CXCL12 (HSmCXCL12). In vitro,
HSmCXCL12 failed to promote transendothelial migration of
PBMCs if used as chemoattractant in the bottom well of tran-
swell plates, and inhibited the haptotactic response to wild-type
CCL7, CXCL12, and CXCL8. Further, intravenous administra-
tion of HSmCXCL12 into mice also repressed the recruitment
of lymphocytes and mononuclear phagocytes to air pouches
injected with CXCL12. Moreover, repetitive administration of
HSmCXCL12 in vivo reduced leukocyte-surface expression of
CXCR4, and CXCL12-induced chemotaxis and adhesion. From
here the authors conclude that non-heparin sulfate-binding vari-
ants of CXCL12 can mediate a powerful anti-inflammatory effect
through induction of chronic CXCR4 internalization on leuko-
cytes in vivo. Subsequently, this leads to receptor desensitization
putatively explaining the functional deficits of these leukocytes
(O’boyle et al., 2009). Hence, it could be interesting to carefully
dissect the differential functional consequences of receptor desen-
sitization through receptor internalization compared to CXCR4
blocking with AMD as reported by Zernecke et al. (2008).
A potential pro-inflammatory role for wild-type CXCL12 may
also be deduced from findings from Liu et al., who revealed
decreased CXCR4 expression on RAW264 cells and primary
human monocytes treated with the H2S releaser GYY4137, which
was introduced above. Administration of GYY4137 into Apoe−/−
mice receiving a high-fat diet for 4 weeks decreased atheroscle-
rotic plaque formation and partially restored aortic endothelium-
dependent relaxation. Further, intercellular adhesion molecule
(ICAM) 1, TNF-α and interleukin (IL) 6 mRNA expression as
well as superoxide generation in the aorta declined inmice treated
with GYY4137 (Liu et al., 2013). Similarly, and again parallel-
ing in vitro studies with human monocytes, CLA treatment
of Apoe−/− mice with already pre-established atherosclerosis
induced lesion regression by reducing leukocyte adhesion and
decreasing CD18 expression on classical monocytes (De Gaetano
et al., 2013).
The above studies may point at a pro-atherogenic role of
CXCR4 signaling in atherosclerosis; however this may strongly
depend on the binding partner interacting with CXCR4. As
already described, CXCL12 is not the only ligand for CXCR4
and MIF, an alternative ligand for CXCR4, has a strong pro-
atherogenic impact. In this context, Bernhagen et al. revealed
that antibody mediated-neutralization of MIF, but not CXCL12,
induced atherosclerotic lesion regression in Apoe−/− mice
(Bernhagen et al., 2007). In line, knock-out of Mif in Ldlr−/−
mice did also result in diminished atherosclerosis (Pan et al.,
2004). This suggests potential different roles of CXCR4 and its
ligand CXCL12 in atherosclerosis through interplay of CXCR4
with MIF. Similarly, interplay of CXCL12 with other signaling
molecules may modify its inflammatory effects. For example,
hetero-complexes of high mobility group box (HMGB) 1 and
CXCL12 were reported to induce inflammatory cell recruitment
to injured tissue, which was not the case for each compound
alone. Further, these complexes exclusively bound to CXCR4
inducing a conformational rearrangement of CXCR4, which dif-
fered from the single binding of CXCL12 to its receptor (Schiraldi
et al., 2012).
Neutrophils
Treatment ofmice with the CXCR4 antagonist AMD3100 induced
cell egress from the bone marrow (Schiraldi et al., 2012), which is
in line with findings by Zernecke et al. who described increased
leukocytosis, mostly neutrophil mobilization, and enhanced
lesion formation in Apoe−/− receiving a cholesterol-rich diet for
12 weeks while supplemented with AMD. Interestingly, mono-
cyte numbers were only moderately enhanced in these mice and,
according to the authors, lesion growth was mainly attributable to
increased plaque neutrophils and enhanced apoptosis (Zernecke
et al., 2008).
Notably, a growing body of evidence underlines the role of
neutrophils in atherogenesis (Drechsler et al., 2010, 2011; Doring
et al., 2012) and it was recognized that the CXCL12/CXCR4
axis maintains neutrophil homeostasis primarily by regulation of
neutrophil release from the bone marrow in a cell-autonomous
fashion (Eash et al., 2009). It was further implicated that senes-
cent neutrophils in the periphery expressing high levels of CXCR4
home back to the bone marrow to be cleared (Martin et al., 2003).
In contrast, activated neutrophils downregulate CXCR4 expres-
sion putatively postponing their clearance (Bruhl et al., 2003;
Martin et al., 2003).
Lymphocytes
CXCR4 on lymphocytes plays an essential role during B-cell
development (Nagasawa et al., 1996) and T-cell homeosta-
sis (Bleul et al., 1996b; Zou et al., 1998). Furthermore, the
CXCL12/CXCR4 axis drives chemotaxis or fugetaxis of T-cells
in various pathophysiological settings (Poznansky et al., 2000;
Dunussi-Joannopoulos et al., 2002; Fernandis et al., 2003; Okabe
et al., 2005; Zhang et al., 2005). Similarly, CXCL12 is able to
trigger B-cell chemotaxis in vitro through CXCR4 (Klasen et al.,
2014).
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It became evident that the impact of B- and T-cells in
atherosclerosis is strongly subset-dependent. While e.g., Th1
responses are known to be pro-atherosclerotic, regulatory T-cells
haven been proven to be protective. Similarly, B1- and B2-
cells exhibit diverse functions in lesion development (Weber and
Noels, 2011). Nevertheless, studies dissecting the role of CXCR4
on T- and B-cells in the context of atherosclerosis are scarce.
Two independent groups showed that lysophosphatidylcholine
(LPC), a main phospholipid component of oxLDL, upregulates
CXCR4 expression on Jurkat cells and human blood CD4+ T-
cells. Further, the chemotactic ability of CD4+ T-cells toward
CXCL12 and their production of pro-inflammatory cytokines
were increased in the presence of LPC. Hence, the ill alliance of
LPC and CXCL12 in atherosclerotic lesions may amplify pro-
inflammatory responses by stimulation of CD4+ T-cells and
subsequent plaque growth (Han et al., 2004; Hara et al., 2008).
Interestingly, it was also shown that excess of mineralocorticoids,
mainly aldosterone, drive CAD by cardiac and renal fibrosis, as
well as hypertension. Here, Chu et al. imply a specific role of the
CXCL12/CXCR4 axis in the detrimental consequences of miner-
alocorticoid excess and render CXCL12 explicitly responsible for
the accumulation of T-cells in fibrotic tissue (Chu et al., 2011).
From patients with abdominal aortic aneurysm (AAA) we fur-
ther learn that T- and B-cells recruited to sites of AAA express
high levels of CXCR4 and exhibit a pro-inflammatory signature.
Hence, CXCR4/CXCL12 interactions may strongly impact on the
recruitment and retention of inflammatory lymphocytes infiltrat-
ing AAAs (Ocana et al., 2008). In contrast, acute stress induced by
public speaking did not enhance the number of CXCR4 express-
ing T-cells, but increased the frequency of T-cells expressing
CXCR2, CXCR3, and CCR5. Therefore, cardiac sympathetic acti-
vation may lead to EC and T-cell activation subsequently driving
acute flooding of atherosclerotic lesions with pro-inflammatory
mediators (Bosch et al., 2003).
In addition to CXCL12-triggered effects, CXCR4 is able to
mediate MIF-induced B-cell chemotaxis, and T-cell chemotaxis
and arrest in vitro (Bernhagen et al., 2007; Klasen et al., 2014).
Blockade of MIF in Apoe−/− mice on high-fat diet resulted in the
formation of smaller atherosclerotic lesions displaying a reduced
macrophage and T-cell content, supporting a role for MIF in T-
cell chemotaxis also in the context of atherosclerosis (Bernhagen
et al., 2007).
Platelets
CXCR4 expression (mRNA, protein) was reported on platelets
(Wang et al., 1998; Kowalska et al., 1999) and although platelets
lack nuclei and many organelles and are mainly known for their
important role in blood coagulation, their impact on immuno-
logical and inflammatory responses, in particular atherosclerosis,
should not be underestimated (Lievens and Von Hundelshausen,
2011). Addition of CXCL12 to platelets from healthy donors
induced platelet aggregation, which could be inhibited by block-
ing CXCR4. The latter implies an atherogenic, pro-thrombotic,
and plaque-destabilizing role for the CXCL12/CXCR4 axis in vivo
(Falk et al., 1995; Abi-Younes et al., 2000). In contrast, oth-
ers report CXCL12 to be a weak platelet agonist, however still
amplifying platelet activation, adhesion and chemokine release
triggered by low doses of primary platelet agonists, such as
adenosine diphosphate (ADP) and thrombin, or arterial flow con-
ditions (Kowalska et al., 1999; Gear et al., 2001). Furthermore,
CXCL12 gradients could induce platelet migration and transmi-
gration in vitro involving PI3K signaling (Kraemer et al., 2010). In
addition, recent work showedCXCL12 to trigger CXCR4 internal-
ization and cyclophilin A-dependent CXCR7 externalization on
(mouse and human) platelets, resulting in prolonged platelet sur-
vival. Mice lacking the cytosolic chaperone cyclophilin A showed
less CXCL12-induced rescue of platelets from activation-induced
apoptosis through CXCR7 engagement. Hence, differential reg-
ulation of CXCR4/CXCR7 surface expression on platelets upon
CXCL12 exposure at sites of platelet activation/accumulationmay
orchestrate platelet survival, subsequently impacting on platelet-
mediated physiological mechanisms (Chatterjee et al., 2014).
Vascular Endothelial Cells
CXCR4 expression in arterial ECs. Expression of CXCR4 on var-
ious types of vascular ECs has been widely reported (Hillyer et al.,
2003), however, it should be emphasized that ECs are a very het-
erogeneous population, with ECs from different anatomic sites
differing in basal gene expression, localization and function (Aird,
2007). Further, one has to carefully distinguish between expres-
sion on venous and arterial ECs (Dela Paz and D’amore, 2009).
Unfortunately, many studies extrapolate e.g., in vitro findings
generated with human umbilical vein endothelial cells (HUVECs)
to arteriosclerosis, which is at least daring.
In a study examining CXCR4 expression following vessel wall
injury in porcine coronary arteries, CXCR4 expression could be
shown 24 h to 7 days after injury, but only in lymphocytes, gran-
ulocytes and myelo-fibroblasts entering the injured tissue (Jabs
et al., 2007). However, others investigated CXCR4 expression in
human carotid artery specimens, where CXCR4 was abundantly
expressed by lesional ECs and only marginally in minimally
diseased endothelium (Molino et al., 2000; Melchionna et al.,
2005). Similarly, Gupta et al. showedCXCR4mRNA expression in
human coronary artery ECs, although it is not clear if these cells
originated from inflamed or steady-state endothelium (Gupta
et al., 1998). CXCR4 was also shown to be expressed (mRNA and
protein) by cultured bovine aortic ECs (BAECs), in cryo-sections
of rabbit thoracic aortas (Volin et al., 1998) and in mouse aortic
endothelium (Melchionna et al., 2010). For BAECs it was further
demonstrated that resting BAECs accumulate CXCR4 protein in
cytoplasmic granules, while migrating BAECs display a diffuse
surface expression of CXCR4 (Feil and Augustin, 1998).
In addition, in vitro studies with human aortic ECs (HAECs)
revealed enhanced CXCR4 surface expression and CXCL12-
induced chemotaxis in the presence of VEGF or basic fibroblast
growth factor (bFGF) 48 h after stimulation. Notably, interferon
(IFN)-γ, lipopolysaccharide (LPS) or CXCL12 did not elevate the
surface expression of CXCR4 (Salcedo et al., 1999).
CXCR4 expression in venous and microvascular ECs.
Upregulation of CXCR4 surface expression after addition of
VEGF and bFGF was also seen in human microvascular ECs and
HUVECs (Salcedo et al., 1999, 2003). In contrast, Schutyser et al.
do not report changes in CXCR4 mRNA expression in human
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microvascular ECs after treatment with VEGF, but describe
augmented CXCR4 expression (mRNA and protein) after serum
starvation and/or hypoxic treatment of microvascular ECs
(Schutyser et al., 2007). Further, hypoxia is also an important
regulator of the CXCL12/CXCR4 axis in HUVECs by enhancing
CXCR4 expression (Ceradini et al., 2004; Jin et al., 2012). In
general hypoxia does cause lowering of local pH, and pH changes
are also known to occur upon physical exercise and hemody-
namic shear stress, as well as in pathological states including
cardiac ischemia. In this context Melchionna et al. reported that
acidosis decreased CXCR4 surface expression on mouse aortic
ECs in vivo and on HUVECs in vitro in a HIF1α-dependent
manner (Melchionna et al., 2010).
Notably, mouse microvascular ECs were also shown to aug-
ment CXCR4 expression in vitro in response to erythromycin,
an anti-inflammatory antibiotic drug used for treatment of
chronic inflammatory diseases. The authors assume that benefi-
cial effects of erythromycin are partly due to CXCR4-expressing
ECs recruited to sites of tissue injury (Takagi et al., 2009).
However, since microvascular ECs also comprise a broad vari-
ety of ECs, for example of dermal, brain, heart or pancreatic
islets origin, it remains elusive how any differential regulation of
CXCR4 expression described above would impact on atheroscle-
rotic plaque development.
Role of CXCR4 in ECs? Concerning possibly relevant functions of
endothelial CXCR4 signaling in context of atherosclerosis, several
putatively athero-relevant findings were described in HUVECs,
but confirmations in arterial ECs are pending. For example, lam-
inar shear stress suppresses CXCR4 expression in HUVECs while
low shear stress favors CXCR4 expression, subsequently result-
ing in increased EC apoptosis and CCL2 and CXCL8 release
(Melchionna et al., 2005).
Another study revealed enhanced release of CXCL12 by
HUVECs after oxLDL treatment and a subsequently increased
migratory and adhesive response of MSCs (Li et al., 2010). It
was further demonstrated that MIF facilitates leukocyte rolling
on stimulated HUVECs while siRNA-mediated knock-down of
endothelial MIF resulted in decreased expression of E-selectin,
ICAM-1, vascular cell adhesionmolecule (VCAM) 1, CXCL8, and
CCL2 (Cheng et al., 2010).
In addition, it seems that not only VEGF may regulate
CXCR4 expression, but it was also shown that CXCL12 treatment
increased VEGF protein expression in human microvascular ECs
after serum starvation (Saxena et al., 2008), underlining the role
of CXCL12 in angiogenesis. Given the CXCL12/CXCR4 axis to be
angiogenic in general (Ara et al., 2005; Unoki et al., 2010), but also
in tumor development (Domanska et al., 2013) and potentially in
atherosclerotic lesions (Di Stefano et al., 2009), and angiogene-
sis being considered to increase plaque vulnerability, the question
still remains if this reflects an important unfavorable role of
CXCR4 in atherosclerosis. In a different approach, blocking of
TLR2 resulted in increased angiogenic capacity of HUVECs, puta-
tively mediated via association of TLR2 with CXCR4 and subse-
quently enhanced CXCR4 signaling. Consequently, knock-down
of CXCR4 in the presence of TLR2 blocking antibodies revealed
less angiogenesis. From these data the authors conclude that TLR2
blocking might serve as a promising therapeutic approach in e.g.,
MI or peripheral artery disease by promoting revascularization.
However, considering angiogenesis pro-atherogenic, TLR2 block-
ing might have detrimental consequences in the context of plaque
stability and development, as already mentioned above (Wagner
et al., 2013). Nevertheless, it was also shown that the inflamma-
tory mediators IFN-γ and TNF-α decrease CXCR4 and CXCL12
expression in HUVECs, thereby decreasing their angiogenic
capacity (Gupta et al., 1998; Salvucci et al., 2004). Interestingly,
the latter contradict findings from Salcedo et al, who showed no
difference in CXCR4 expression in HAECs after IFN-γ treatment
(Salcedo et al., 1999). Yet, it should be emphasized again that
HUVECs and HAECs might exert totally different responses in
the presence of the same stimulus, underlining again the impor-
tance of caution in generalizing findings from ECs of different
origin.
Vascular smooth muscle cells
VSMCs are highly specialized cells controlling contraction and
regulation of blood vessel diameter, blood pressure, and blood
flow. Moreover, VSMCs play a critical role in secretion of extra-
cellular matrix components, which determine the mechanical
properties of mature blood vessels. Differentiated VSMCs in adult
blood vessels proliferate at very low rates and retain high plastic-
ity, which enables changes in phenotype, referred to as phenotypic
switching (Owens et al., 2004). Phenotypic switching of VSMCs
is considered an important pathophysiological mechanism in
atherosclerosis (Gomez and Owens, 2012).
CXCR4 expression in vascular SMCs. Not much is known about
the expression and function of CXCR4 in mature VSMCs. Several
studies reported no CXCR4 expression on human or bovine
(aortic) SMCs (Gupta et al., 1998; Volin et al., 1998). In con-
trast, Schecter et al. were the first to claim a functional CXCR4
expression on human aortic SMCs, as the addition of CXCL12 or
envelope proteins of HIV specifically binding CXCR4 did induce
tissue factor activity in human aortic SMCs (Schecter et al.,
2001). Similarly, it was demonstrated that HIV can infect arterial
(lesional) human SMCs and blocking CXCR4 in human aortic
SMCs in vitro did significantly reduce their viral load. Again,
direct expression of CXCR4 on aortic SMCs was not investigated.
Yet, the authors still claim that HIV infection of VSMCs through
CXCR4 may be one reason why HIV patients are more suscepti-
ble to develop atherosclerosis (Eugenin et al., 2008). Nevertheless,
Li et al. revealed CXCR4 protein expression on human saphe-
nous vein SMCs (Li et al., 2009) and others later reported CXCR4
expression (RNA, protein) on mouse medial SMCs (Nemenoff
et al., 2008), rat aortic SMCs (Jie et al., 2010; Pan et al., 2012)
and human aortic SMCs (Weber et al., unpublished data).
Role of CXCR4 in vascular SMCs? As mentioned before, pheno-
typic switching of VSMCs from a contractile to a synthetic secre-
tory phenotype and their assumed migration from the medial
to the intimal arterial wall, where they secrete pro-inflammatory
mediators, is considered a pathophysiological mechanism in
atherogenesis (Gomez and Owens, 2012). On the other hand,
intimal SMCs do also stabilize atherosclerotic lesions by fibrous
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cap formation. This contrasts the pathology of injury-induced
restenosis and neointimal hyperplasia, which are mainly driven
by SMC proliferation. Hence, the contribution of SMCs to lesion
formation is strongly context-dependent.
In a rat model of diabetes, a metabolic disorder associated with
a higher prevalence of atherosclerosis, high glucose levels were
shown to trigger activation, proliferation, and enhanced chemo-
taxis of VSMCs via stimulation of the CXCL12/CXCR4 axis (Jie
et al., 2010). Correspondingly, salvianolic acid B (Salvia miltior-
rhiza), used to treat cardiovascular diseases in traditional Chinese
medicine, was shown to inhibit CXCL12/CXCR4-mediated pro-
liferation, migration and subsequently neointimal hyperplasia by
VSMCs in a balloon angioplasty-induced neointima formation
model in rats. Here salvianolic acid B directly decreased surface
expression of CXCR4 on aortic rat SMCs (Pan et al., 2012).
Further, lesion reduction in Mif−/−Apoe−/− mice was
attributed to a reduction in lesional SMC proliferation, cysteine
protease expression, and elastinolytic and collagenolytic activities
(Pan et al., 2004). Notably, oxLDL, supposed to be an impor-
tant trigger of atherogenesis and plaque growth, was shown to
induce rat aortic SMC proliferation. This effect could even be
further enhanced by addition of CXCL12 and came along with
diminished SMC apoptosis. It remains open if this effect would
be beneficial through plaque stabilization, or detrimental because
of intimal hyperplasia, as discussed above (Li et al., 2013). As
mentioned before, vein graft failure after bypass grafting is a
major problem and may be associated with neointimal hyperpla-
sia and accelerated atherosclerosis. In this context, Zhang et al.
demonstrate that CXCL12/CXCR4 signaling might be a crucial
step in vein graft atherosclerosis and contribute to SMC-mediated
vein graft neointimal hyperplasia in mice. Furthermore, CXCR4-
mediated recruitment of inflammatory (progenitor) cells to the
vein graft may add to this picture (Zhang et al., 2012).
Also, it was described that CXCL12 stimulates pro-MMP2
expression in human aortic SMCs via CXCR4 in association
with the epidermal growth factor receptor in vitro. The authors
conclude that CXCR4 expands its signaling repertoire by cross-
talking with other receptors, pointing at an important role of
ligands engaged in receptor cross-talk as critical players in CAD
(Kodali et al., 2006).
GENOME-WIDE ASSOCIATION STUDIES REVEAL CXCL12 AS
AN IMPORTANT CANDIDATE GENE IN CAD
Genome-wide association studies of European ancestry revealed
2 single nucleotide polymorphisms (SNPs) on locus 10q11.21, 80
kB downstream of CXCL12, to be significantly associated with
CAD and MI (Burton et al., 2007; Samani et al., 2007; Kathiresan
et al., 2009; Farouk et al., 2010; Schunkert et al., 2011), although
genome-wide significance was not reached in 2 other studies
(Ripatti et al., 2010; Peden et al., 2011) (Box 4). Whether and how
the risk alleles of these SNPs rs1746048(C/C) and rs501120(T/T)
affect expression level and/or function of the CXCL12 protein is
currently still unclear.
A significant association was revealed between the CAD risk
genotype for rs501120 (T/T) and reduced CXCL12 plasma lev-
els (Kiechl et al., 2010). Likewise, patients with angina displayed
reduced CXCL12 plasma levels compared to healthy controls. The
reduction was even higher in case of unstable disease (Damas
et al., 2002), suggesting an atheroprotective role for CXCL12.
Remarkably, patients with angina showed a significant reduction
in CXCR4 surface expression on PBMCs, despite increased levels
of CXCR4 RNA transcripts, but its connection to disease remains
unclear (Damas et al., 2002).
In contrast, a recent study revealed the risk alleles of these SNPs
to be associated with higher CXCL12 plasma levels, rather sug-
gesting a pro-atherogenic role for CXCL12 (Mehta et al., 2011).
Additional large-scale studies in human patients with CAD/MI
investigating CXCL12 plasma levels in relation to SNPs and dis-
ease would be helpful to get better insight into the role of CXCL12
in this pathology. Furthermore, animal studies are definitively
required to unravel disease-associated functions in a cell-specific
and molecular way.
Also for the alternative CXCR4 ligand MIF, SNPs have been
identified that are associated with cardiovascular disease, as
recently summarized (Tillmann et al., 2013). Although the effect
of these SNPs on MIF expression or function remain unknown,
enhanced MIF plasma levels in patients with ACS (Muller et al.,
2012) and the identification of a high MIF plasma level as a risk
factor for adverse coronary events in CAD patients with impaired
glucose tolerance or type 2 diabetes mellitus (Makino et al., 2010)
may support a pro-inflammatory role of plasma MIF in CAD.
CLINICAL PERSPECTIVES AND CONCLUSION
In conclusion, the role of CXCR4 in native atherosclerosis remains
elusive, with only few isolated studies shedding some light on
the effect of CXCL12/CXCR4 signaling on cell type-specific
functions involved in inflammation or atherosclerosis. In con-
trast, the CXCL12/CXCR4 axis has been better explored in con-
text of injury-induced restenosis and myocardial ischemia, in
which a role for this chemokine ligand/receptor axis has mostly
been linked to the mobilization and recruitment of progeni-
tor cells and, to a lesser extent, inflammatory cells (Figure 3).
The CXCR4 antagonist AMD3100, also known as Plerixafor,
has been approved as mobilizer of hematopoietic stem cells in
combination with G-CSF in treatment of patients with non-
Hodgkin’s lymphoma and multiple myeloma, and many other
small molecule inhibitors of CXCR4 are in clinical trial or
under investigation (Debnath et al., 2013). However, a poten-
tial future application of such inhibitors in treatment of patients
with CAD is currently only speculative. Although mobilization
of progenitor cells has been associated with cardioprotection
in context of myocardial ischemia and also initial clinical trials
for stem cell therapy after MI are encouraging, many impor-
tant aspects of such therapy—as optimal cell type, dose, time
and method of administration, long-term effects—remain to be
investigated (Sanganalmath and Bolli, 2013). Furthermore, con-
trasting reports on the effect of AMD3100 treatment on cardiac
outcome after MI warns for a further evaluation of underlying
mechanisms, and also the recently revealed double-edged role
of CXCR4 in myocardial ischemia necessitates a careful eval-
uation of drugs interfering with CXCL12/CXCR4 signaling. In
addition, possible unwanted side effects need to be cautiously
monitored. For example, one patient study examining the effects
of progenitor cell mobilization on cardiac function after MI
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FIGURE 3 | Involvement of CXCR4 in CAD. The chemokine receptor CXCR4
plays a role in angiogenesis. Furthermore, it is an important regulator of
homing, mobilization and survival of progenitor cells. This has linked CXCR4
with a role in myocardial ischemia and injury-induced restenosis, but its
significance in the context of native atherosclerosis remains unclear. CXCR4
has also been reported to mediate leukocyte chemotaxis in specific
inflammatory diseases. A similar role in inflammatory cell recruitment has
been suggested in the context of myocardial ischemia, but the importance of
CXCR4-induced leukocyte recruitment to atherosclerotic lesions in vivo
remains to be further addressed. The current view mainly emphasizes the
involvement of inflammatory chemokines instead of the homeostatic
chemokine CXCL12 in mediating atherogenic leukocyte recruitment.
However, CXCR4 can mediate both CXCL12- and MIF-induced chemotaxis of
B- and T-cells in vitro, and is also expressed on a subset of monocytes,
requiring further research of its function in atherogenic leukocyte recruitment
in vivo. Also, it remains unclear which cell type-specific functions of CXCR4
may be important in context of atherosclerosis, with currently only scarce
information on potential cellular functions in most cell types present in
atherosclerotic lesions. For more details, we refer to the text. Green arrows
indicate beneficial effects, red arrows indicate detrimental effects. The
interrelation between different pathologies belonging to CAD is visualized.
The lower panels indicate relevance of CXCR4-involving cell type-specific
functions to atherosclerotic plaque formation. bFGF, basic fibroblast growth
factor; CAD, coronary artery disease; H2S, hydrogen sulfide; M-CSF,
macrophage colony stimulating factor; MMP, matrix metallopeptidase; oxLDL,
oxidized low-density lipoprotein; VEGF, vascular endothelial growth factor.
was terminated early due to enhanced in-stent restenosis (Kang
et al., 2004). Also, a closer investigation of the effect of CXCR4
antagonists on progenitor cell mobilization in context of differ-
ent cardiovascular disease settings or upon different dosage or
administration methods seems interesting, as contrasting find-
ings were reported on the effect of continuous administration
of the CXCR4 antagonist AMD3465 on the mobilization of
Lin−Sca1+ cells in context of native atherosclerosis vs injury-
induced restenosis (Karshovska et al., 2008; Zernecke et al.,
2008).
Furthermore, additional studies are required to unravel in
more detail the cellular processes in which CXCR4 is involved
and the underlying molecular mechanisms. In this context,
complexness of CXCR4-associated biological and mechanistic
aspects is significantly being increased by the identification
of MIF as a secondary chemokine ligand for CXCR4, and
of CXCR7 as an alternative receptor for CXCL12. Intertwining
of chemokine receptor signaling may enhance fine tuning and
optimization of leukocyte chemotaxis in physiological condi-
tions. In addition, it may increase the possibilities for designing
therapeutics interfering with only selective aspects of chemokine
signaling, for example by targeting chemokine receptor het-
erodimerization (Koenen and Weber, 2010). But again, this
necessitates a better understanding of biological and mechanistic
aspects of all involved chemokine ligand/receptor axes and their
interplay.
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